25 results on '"Gintant, Gary A."'
Search Results
2. Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute
3. Automated blood sampling in canine telemetry studies: Enabling enhanced assessments of cardiovascular liabilities and safety margins
4. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs
5. Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms
6. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
7. A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat
8. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress
9. Human ex-vivo action potential model for pro-arrhythmia risk assessment
10. How do the top 12 pharmaceutical companies operate safety pharmacology?
11. Ventricular rate adaptation: A novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds
12. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics
13. Drug-induced QT prolongation: Concordance of preclinical canine model in relation to clinical outcome
14. The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and d, l-sotalol
15. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation
16. Prediction of drug-effects on cardiac repolarization in humans: What can we learn from the past to refine our drug discovery strategies?
17. The [ 3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K +] o
18. The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell-derived cardiomyocytes
19. Can Nonclinical Repolarization Assays Predict the Results of Clinical Thorough QT Studies? A HESI-FDA Retrospective Analysis
20. How do large pharmaceutical companies mitigate concerns of drug-induced QT prolongation in drug discovery?
21. WITHDRAWN: Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics
22. An analysis of safety pharmacology operations across the top 12 pharmaceutical companies
23. Assessing concordance of nonclinical and clinical QT data: The ILSI-HESI cardiovascular safety subcommittee initiative re-visited
24. AN IN VITRO EXAMINATION OF DELAYED REPOLARIZATION: HOW PLASMA PROTEIN BINDING INFLUENCES DRUG EFFECTS
25. How do large pharmaceutical companies mitigate concerns of drug-induced QT prolongation in drug discovery?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.